Engineered immune cells take on Hard-to-Treat cancers

NCT ID NCT05672459

Ongoing Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests a new treatment called IVS-3001, which uses a patient's own immune cells (T cells) engineered to target a protein called HLA-G found on some solid tumors. The study involves 31 adults with advanced solid tumors that have not responded to standard treatments. Participants receive the engineered cells through an IV, along with chemotherapy drugs to prepare the body. The main goals are to check safety and see if the treatment shrinks tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HLA-G-targeted CAR-T cells (IVS-3001)
What this could lead to: If it works, this could point toward a new treatment option for people with advanced solid tumors that have stopped responding to standard therapies.
What could go wrong: This is an early phase 1/2a trial with only 31 participants, so results may not apply broadly. CAR-T cell therapy can cause serious side effects like cytokine release syndrome.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CLEAR CELL RENAL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

kidney cancer neoplasm nonpapillary renal cell carcinoma ovarian carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMOR

Contacts and locations

Locations

M D Anderson Cancer Center

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.